Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(38%)
Results Posted
150%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph not_applicable
2
25%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Completed2
Recruiting2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (60.0%)
N/A2 (40.0%)

Trials by Status

unknown225%
terminated113%
completed225%
active_not_recruiting113%
recruiting225%

Recent Activity

3 active trials
Showing 5 of 8
recruiting

White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)

NCT07103681
recruitingnot_applicable

Long-term Longitudinal Imaging of Presynaptic Terminals in PD

NCT06875765
active_not_recruitingphase_1

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
completedphase_1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

NCT03448393
terminatedphase_1

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07103681

White Matter Distortion and Dementia Biomarkers in Normal Pressure Hydrocephalus (NPH)

Recruiting
NCT06875765Not Applicable

Long-term Longitudinal Imaging of Presynaptic Terminals in PD

Recruiting
NCT02911142Phase 1

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Active Not Recruiting
NCT03448393Phase 1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Completed
NCT04933617Phase 1

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated
NCT03483220

Emotional Regulation, Impulsivity in Cannabis Its Relation to MRI Brain Structure

Completed
NCT04162587

Extracranial Carotid & Intracranial Arterial Stenosis in Ischemic Stroke

Unknown
NCT02756416Not Applicable

Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
8